(0)
Iris Bincovich, CEO will participate on the CBD Treatments discussion panel on Monday June 14 at 11:00AM ET.
Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - June 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the Company or Innocan ), is pleased to announce that it will participate at the Lytham Partners Summer 2021 Investor Conference on June 14 through June 16, 2021. Iris Bincovich, CEO of Innocan will participate on the CBD Treatments discussion panel alongside representatives from cbdMD, Charlotte s Web, CV Science Inc, and Avicanna on Monday June 14 at 11:00AM ET. A webcast of the presentation will be available on Innocan s website at
Innocan Pharma Corporation: Innocan Pharma s CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Company or
Innocan ), is pleased to announce today that a recent study conducted in mice based on Innocan s licensed CBD-loaded liposome platform technology (LPT) for injectable CDB solutions demonstrated a prolonged release of cannabidiol (CBD) into the mice s bloodstream for at least 50 days following two injections. This study was led by Dr. Ahuva Cern, a senior researcher in the lab of Prof. Barenholz of The Hebrew University of Jerusalem.
These results are significant in comparison to oral or inhalation-based intake methods, in which CBD is found to remain in the bloodstream for a maximum-period of 36 hours following a single dose. These results open the door to a wide range of exciting therapeutic possibilities.
Innocan Pharma Corporation: Innocan Pharma and Polyflame Announce an Exclusive Distribution Agreement in France finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - April 6, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the Company or Innocan ) is proud to announce the addition of Richard Serbin
to its Advisory Committee. Richard Serbin will work closely with Innocan s leadership to address the emerging global Pharma opportunities, to expand Innocan s presence as part of its growth strategy, and to contribute from his extensive experience as Johnson & Johnson s Executive Vice President of Corporate Development, as former board member of more than 16 companies and, especially in regard to FDA regulations.
Richard Serbin
https://orders.newsfilecorp.com/files/6922/79561 51715afec4670a32 002full.jpg
Innocan Pharma Corporation: Innocan Pharma Announces Proceeds of CDN $ 3 1M from the Exercise of Warrants Since January 1, 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.